{"transactions":[{"id":1354452,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-11-22T21:12:35.000Z","date":"2024-11-20","kind":"sale","planned":false,"acquired":false,"shares":3650,"price":25.45,"value":92892.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 17, 2022, the holder was granted 112,816 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.91 - $25.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":319228,"source":{"system":"sec-edgar","filing":"0001764013-24-000196","document":"wk-form4_1732309949.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000196/wk-form4_1732309949.xml","form_type":"4"}},{"id":1381334,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-10-25T20:25:04.000Z","date":"2024-10-23","kind":"sale","planned":false,"acquired":false,"shares":4361,"price":29.53,"value":128780.33,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 28, 2022, the holder was granted 143,000 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,937 of these RSUs vested on October 19, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.38 - $29.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":322878,"source":{"system":"sec-edgar","filing":"0001764013-24-000180","document":"wk-form4_1729887897.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000180/wk-form4_1729887897.xml","form_type":"4"}},{"id":1384131,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-10-18T20:28:55.000Z","date":"2024-10-16","kind":"sale","planned":false,"acquired":false,"shares":2860,"price":28.79,"value":82339.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 12, 2023, the holder was granted 87,664 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on October 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.31 - $29.14 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":327239,"source":{"system":"sec-edgar","filing":"0001764013-24-000172","document":"wk-form4_1729283330.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000172/wk-form4_1729283330.xml","form_type":"4"}},{"id":1424332,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-08-23T20:15:34.000Z","date":"2024-08-21","kind":"sale","planned":false,"acquired":false,"shares":131,"price":32.32,"value":4233.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 17, 2022, the holder was granted 112,816 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on August 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.28 - $32.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":330099,"source":{"system":"sec-edgar","filing":"0001764013-24-000160","document":"wk-form4_1724444128.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000160/wk-form4_1724444128.xml","form_type":"4"}},{"id":1424331,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-08-23T20:15:34.000Z","date":"2024-08-21","kind":"sale","planned":false,"acquired":false,"shares":3164,"price":31.84,"value":100741.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 17, 2022, the holder was granted 112,816 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on August 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 - $32.25 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":330230,"source":{"system":"sec-edgar","filing":"0001764013-24-000160","document":"wk-form4_1724444128.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000160/wk-form4_1724444128.xml","form_type":"4"}},{"id":1448100,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-07-26T20:17:01.000Z","date":"2024-07-24","kind":"sale","planned":false,"acquired":false,"shares":4015,"price":27.76,"value":111456.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 28, 2022, the holder was granted 143,000 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,938 of these RSUs vested on July 19, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.37 - $28.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":333394,"source":{"system":"sec-edgar","filing":"0001764013-24-000141","document":"wk-form4_1722025015.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000141/wk-form4_1722025015.xml","form_type":"4"}},{"id":1451228,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-07-19T21:42:37.000Z","date":"2024-07-17","kind":"sale","planned":false,"acquired":false,"shares":147,"price":30.55,"value":4490.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 12, 2023, the holder was granted 87,664 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on July 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 - $30.84 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":337409,"source":{"system":"sec-edgar","filing":"0001764013-24-000137","document":"wk-form4_1721425350.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000137/wk-form4_1721425350.xml","form_type":"4"}},{"id":1451227,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-07-19T21:42:37.000Z","date":"2024-07-17","kind":"sale","planned":false,"acquired":false,"shares":2358,"price":29.64,"value":69891.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 12, 2023, the holder was granted 87,664 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on July 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 - $30.28 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":337556,"source":{"system":"sec-edgar","filing":"0001764013-24-000137","document":"wk-form4_1721425350.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000137/wk-form4_1721425350.xml","form_type":"4"}},{"id":1502133,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-05-24T20:10:35.000Z","date":"2024-05-22","kind":"sale","planned":false,"acquired":false,"shares":3242,"price":29.65,"value":96125.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 17, 2022, the holder was granted 112,816 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on May 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.31 - $30.02 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":339914,"source":{"system":"sec-edgar","filing":"0001764013-24-000095","document":"wk-form4_1716581406.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000095/wk-form4_1716581406.xml","form_type":"4"}},{"id":1534823,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-04-26T21:18:36.000Z","date":"2024-04-24","kind":"sale","planned":false,"acquired":false,"shares":3963,"price":28.9,"value":114530.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 28, 2022, the holder was granted 143,000 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,937 of these RSUs vested on April 19, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":343156,"source":{"system":"sec-edgar","filing":"0001764013-24-000085","document":"wk-form4_1714166305.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000085/wk-form4_1714166305.xml","form_type":"4"}},{"id":1538446,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-04-19T22:06:59.000Z","date":"2024-04-17","kind":"sale","planned":false,"acquired":false,"shares":2225,"price":29.94,"value":66616.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 12, 2023, the holder was granted 87,664 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on April 14, 2023, of which 21,916 of these RSUs vested on April 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.43 - $30.20 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":347119,"source":{"system":"sec-edgar","filing":"0001764013-24-000083","document":"wk-form4_1713564410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000083/wk-form4_1713564410.xml","form_type":"4"}},{"id":1538445,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-04-19T22:06:59.000Z","date":"2024-04-17","kind":"sale","planned":false,"acquired":false,"shares":7602,"price":28.8,"value":218937.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 12, 2023, the holder was granted 87,664 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on April 14, 2023, of which 21,916 of these RSUs vested on April 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.43 - $29.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":349344,"source":{"system":"sec-edgar","filing":"0001764013-24-000083","document":"wk-form4_1713564410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000083/wk-form4_1713564410.xml","form_type":"4"}},{"id":1547831,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-04T20:37:07.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":68723,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the options will vest as to 25% of the shares on April 2, 2025 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":68723,"derivative":{"exercise_price":30.78,"expiration_date":"2034-04-02","underlying":"Common Stock","underlying_shares":68723},"source":{"system":"sec-edgar","filing":"0001764013-24-000055","document":"wk-form4_1712263016.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000055/wk-form4_1712263016.xml","form_type":"4"}},{"id":1547830,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-04-04T20:37:07.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":54978,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 2, 2025, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":356946,"source":{"system":"sec-edgar","filing":"0001764013-24-000055","document":"wk-form4_1712263016.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000055/wk-form4_1712263016.xml","form_type":"4"}},{"id":1622710,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-02-23T21:18:52.000Z","date":"2024-02-22","kind":"sale","planned":false,"acquired":false,"shares":2134,"price":36.15,"value":77144.1,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On August 17, 2022, the holder was granted 112,816 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on February 17, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.85 - $36.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":301968,"source":{"system":"sec-edgar","filing":"0001764013-24-000040","document":"wk-form4_1708723115.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000040/wk-form4_1708723115.xml","form_type":"4"}},{"id":1668199,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-01-29T21:12:54.000Z","date":"2024-01-26","kind":"sale","planned":false,"acquired":false,"shares":46,"price":38.45,"value":1768.7,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 28, 2022, the holder was granted 143,000 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,938 of these RSUs vested on January 19, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.45 - $38.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":304102,"source":{"system":"sec-edgar","filing":"0001764013-24-000018","document":"wk-form4_1706562754.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000018/wk-form4_1706562754.xml","form_type":"4"}},{"id":1668198,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-01-29T21:12:54.000Z","date":"2024-01-26","kind":"sale","planned":false,"acquired":false,"shares":2981,"price":37.91,"value":113009.71,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 28, 2022, the holder was granted 143,000 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,938 of these RSUs vested on January 19, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.44 - $38.41 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":304148,"source":{"system":"sec-edgar","filing":"0001764013-24-000018","document":"wk-form4_1706562754.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000018/wk-form4_1706562754.xml","form_type":"4"}},{"id":1730332,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-11-24T19:41:27.000Z","date":"2023-11-22","kind":"sale","planned":false,"acquired":false,"shares":124,"price":33.52,"value":4156.48,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On August 17, 2022, the holder was granted 112,816 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $33.46 - $33.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":307129,"source":{"system":"sec-edgar","filing":"0001764013-23-000137","document":"wk-form4_1700854876.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000137/wk-form4_1700854876.xml","form_type":"4"}},{"id":1730331,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-11-24T19:41:27.000Z","date":"2023-11-22","kind":"sale","planned":false,"acquired":false,"shares":3128,"price":32.75,"value":102442.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On August 17, 2022, the holder was granted 112,816 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $32.43 - $33.38 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":307253,"source":{"system":"sec-edgar","filing":"0001764013-23-000137","document":"wk-form4_1700854876.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000137/wk-form4_1700854876.xml","form_type":"4"}},{"id":1754330,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-10-27T20:04:03.000Z","date":"2023-10-25","kind":"sale","planned":false,"acquired":false,"shares":4107,"price":34.66,"value":142348.62,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 28, 2022, the holder was granted 143,000 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,937 of these RSUs vested on October 19,\n2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $34.66 - $34.83 per share, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":310381,"source":{"system":"sec-edgar","filing":"0001764013-23-000125","document":"wk-form4_1698437034.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000125/wk-form4_1698437034.xml","form_type":"4"}},{"id":1796415,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-08-25T21:05:29.000Z","date":"2023-08-24","kind":"sale","planned":false,"acquired":false,"shares":1,"price":20.89,"value":20.89,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On August 17, 2022, the holder was granted 112,816 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on August 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder."}],"balance_after":314488,"source":{"system":"sec-edgar","filing":"0001764013-23-000105","document":"wf-form4_169299751230736.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000105/wf-form4_169299751230736.xml","form_type":"4"}},{"id":1796414,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-08-25T21:05:29.000Z","date":"2023-08-24","kind":"sale","planned":false,"acquired":false,"shares":12285,"price":20.3,"value":249385.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On August 17, 2022, the holder was granted 112,816 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on August 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.87 - $20.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":314489,"source":{"system":"sec-edgar","filing":"0001764013-23-000105","document":"wf-form4_169299751230736.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000105/wf-form4_169299751230736.xml","form_type":"4"}},{"id":1822225,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-07-27T20:33:09.000Z","date":"2023-07-26","kind":"sale","planned":false,"acquired":false,"shares":3917,"price":21.63,"value":84724.71,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 28, 2022, the holder was granted 143,000 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,938 of these RSUs vested on July 19, 2023.Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.27 - $21.63 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":326774,"source":{"system":"sec-edgar","filing":"0001764013-23-000084","document":"wf-form4_169048996715033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000084/wf-form4_169048996715033.xml","form_type":"4"}},{"id":1913379,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-04-26T20:08:26.000Z","date":"2023-04-25","kind":"sale","planned":false,"acquired":false,"shares":2633,"price":16.29,"value":42891.57,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 28, 2022, the holder was granted 143,000 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,937 of these RSUs vested on April 19, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.11 - $16.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":330691,"source":{"system":"sec-edgar","filing":"0001764013-23-000059","document":"wf-form4_168253969335957.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000059/wf-form4_168253969335957.xml","form_type":"4"}},{"id":1919629,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-14T20:24:08.000Z","date":"2023-04-12","kind":"grant","planned":false,"acquired":true,"shares":113821,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on April 12, 2024 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date."}],"balance_after":113821,"derivative":{"exercise_price":14.7,"expiration_date":"2033-04-12","underlying":"Common Stock","underlying_shares":113821},"source":{"system":"sec-edgar","filing":"0001764013-23-000041","document":"wf-form4_168150383601971.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000041/wf-form4_168150383601971.xml","form_type":"4"}},{"id":1919628,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-04-14T20:24:08.000Z","date":"2023-04-12","kind":"grant","planned":false,"acquired":true,"shares":87664,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the number of shares underlying restricted stock units awards (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs vest over four years, with 25% of the RSUs vesting on April 12, 2024 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date."}],"balance_after":333324,"source":{"system":"sec-edgar","filing":"0001764013-23-000041","document":"wf-form4_168150383601971.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000041/wf-form4_168150383601971.xml","form_type":"4"}},{"id":2043789,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-01-27T12:20:19.000Z","date":"2023-01-26","kind":"sale","acquired":false,"shares":10156,"price":18.51,"value":187987.56,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 28, 2022, the holder was granted 143,000 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on January 31, 2022, of which 35,750 of these RSUs vested on January 19, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder."}],"balance_after":245660,"source":{"system":"sec-edgar","filing":"0001764013-23-000015","document":"wf-form4_167482200506238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000015/wf-form4_167482200506238.xml","form_type":"4"}},{"id":2178377,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-08-19T20:57:57.000Z","date":"2022-08-17","kind":"grant","acquired":true,"shares":169648,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on August 17, 2023 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date."}],"balance_after":169648,"derivative":{"exercise_price":4.99,"expiration_date":"2032-08-17","underlying":"Common Stock","underlying_shares":169648},"source":{"system":"sec-edgar","filing":"0001764013-22-000107","document":"wf-form4_166094266063739.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000107/wf-form4_166094266063739.xml","form_type":"4"}},{"id":2178376,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-08-19T20:57:57.000Z","date":"2022-08-17","kind":"grant","acquired":true,"shares":112816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the number of shares underlying restricted stock units awards (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs vest over four years, with 25% of the RSUs vesting on August 17, 2023 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date."}],"balance_after":255816,"source":{"system":"sec-edgar","filing":"0001764013-22-000107","document":"wf-form4_166094266063739.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000107/wf-form4_166094266063739.xml","form_type":"4"}},{"id":2421167,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-31T22:01:30.000Z","date":"2022-01-28","kind":"grant","acquired":true,"shares":383000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on January 19, 2023 and the remainder of the shares underlying the options vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date."}],"balance_after":383000,"derivative":{"exercise_price":6.72,"expiration_date":"2032-01-28","underlying":"Common Stock","underlying_shares":383000},"source":{"system":"sec-edgar","filing":"0001764013-22-000027","document":"wf-form4_164366644858148.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000027/wf-form4_164366644858148.xml","form_type":"4"}},{"id":2421166,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-01-31T22:01:30.000Z","date":"2022-01-28","kind":"grant","acquired":true,"shares":143000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the number of shares underlying restricted stock units awards (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs vest over four years, with 25% of the RSUs vesting on January 19, 2023 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date."}],"balance_after":143000,"source":{"system":"sec-edgar","filing":"0001764013-22-000027","document":"wf-form4_164366644858148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000027/wf-form4_164366644858148.xml","form_type":"4"}},{"id":2502582,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-19T10:08:00.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":11.41,"expiration_date":"2031-02-28","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-065712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065712/doc4.xml","form_type":"4"}},{"id":2502581,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-19T10:08:00.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":15500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":15.78,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001209191-21-065712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065712/doc4.xml","form_type":"4"}},{"id":2502580,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-19T10:08:00.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":14.75,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-21-065712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065712/doc4.xml","form_type":"4"}},{"id":2502579,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-19T10:08:00.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":33333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":22.31,"expiration_date":"2028-01-31","underlying":"Common Stock","underlying_shares":33333},"source":{"system":"sec-edgar","filing":"0001209191-21-065712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065712/doc4.xml","form_type":"4"}},{"id":2502578,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-19T10:08:00.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":21.74,"expiration_date":"2027-06-25","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-21-065712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065712/doc4.xml","form_type":"4"}},{"id":2502577,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2021-11-19T10:08:00.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":133486,"price":8.5,"value":1134631.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. (\"Issuer\"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. (\"Purchaser\") (\"Merger Agreement\"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation (\"Merger\"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash (\"Cash Amount\"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 (\"CVR Payments\"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the effective time of the Merger, each outstanding restricted stock unit award (\"RSU\") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-065712","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065712/doc4.xml","form_type":"4"}},{"id":2629157,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2021-07-20T20:45:42.000Z","date":"2021-07-19","kind":"sale","acquired":false,"shares":3945,"price":6.45,"value":25445.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares of common stock to cover tax withholding obligations associated with the vesting of restricted stock unit award granted to the Reporting Person on July 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $6.45.  The shares were sold at a range of prices between $6.24 and $6.46.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":133486,"source":{"system":"sec-edgar","filing":"0001209191-21-047502","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121047502/doc4.xml","form_type":"4"}},{"id":2812634,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock option (right to buy)","published_at":"2021-03-03T18:31:34.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares shall vest on the one-year anniversary of January 1, 2021 (the \"Vesting Commencement Date\"), and thereafter 1/48th of the total shares shall vest each month following the one-year anniversary of the Vesting Commencement Date, so that all of the shares shall be vested four years after the Vesting Commencement Date."}],"balance_after":20000,"derivative":{"exercise_price":11.41,"expiration_date":"2031-02-28","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-017262","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121017262/doc4.xml","form_type":"4"}},{"id":2812633,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2021-03-03T18:31:34.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan."}],"balance_after":137431,"source":{"system":"sec-edgar","filing":"0001209191-21-017262","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121017262/doc4.xml","form_type":"4"}},{"id":2913590,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2021-01-07T17:52:47.000Z","date":"2021-01-05","kind":"sale","acquired":false,"shares":6829,"price":11.13,"value":76006.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares of common stock to cover tax withholding obligations associated with the vesting of restricted stock unit awards granted to the Reporting Person on February 1, 2018, March 1, 2019, and March 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $11.13.  The shares were sold at a range of prices between $11.12 and $11.55.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":107431,"source":{"system":"sec-edgar","filing":"0001209191-21-002559","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121002559/doc4.xml","form_type":"4"}},{"id":3079499,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2020-07-20T21:24:58.000Z","date":"2020-07-16","kind":"grant","acquired":true,"shares":38750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. 1/3 of the shares subject to the restricted stock unit award vest on each of July 16, 2021, July 16, 2022 and July 16, 2023."}],"balance_after":114260,"source":{"system":"sec-edgar","filing":"0001209191-20-043108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120043108/doc4.xml","form_type":"4"}},{"id":3100783,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2020-06-24T16:12:40.000Z","date":"2020-06-22","kind":"grant","acquired":true,"shares":1023,"price":10.83,"value":11079.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being filed voluntarily to report the acquisition of 1,023 shares by the Reporting Person on June 22, 2020 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":75510,"source":{"system":"sec-edgar","filing":"0001209191-20-038722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120038722/doc4.xml","form_type":"4"}},{"id":3231967,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock option (right to buy)","published_at":"2020-03-03T16:16:13.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares shall vest on the one year anniversary of January 1, 2020 (the \"Vesting Commencement Date\") and thereafter one-forty-eighth (1/48th) of the total shares shall vest each month following the one year anniversary of the Vesting Commencement Date, so that all of the shares shall be vested four (4) years after the Vesting Commencement Date."}],"balance_after":15500,"derivative":{"exercise_price":15.78,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001209191-20-015128","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120015128/doc4.xml","form_type":"4"}},{"id":3231966,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2020-03-03T16:16:13.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan."}],"balance_after":74487,"source":{"system":"sec-edgar","filing":"0001209191-20-015128","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120015128/doc4.xml","form_type":"4"}},{"id":3316224,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2020-01-07T16:35:41.000Z","date":"2020-01-03","kind":"sale","acquired":false,"shares":3724,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares of common stock to cover tax withholding obligations associated with the vesting of restricted stock unit award granted to the Reporting Person on February 1, 2018 and March 1, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at a range of prices between $19.74 and $19.82.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 938 shares of Common Stock that were acquired by the Reporting Person on December 20, 2019 at $9.89 per share pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":43487,"source":{"system":"sec-edgar","filing":"0001209191-20-002285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120002285/doc4.xml","form_type":"4"}},{"id":3479986,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2019-06-24T16:14:45.000Z","date":"2019-06-21","kind":"grant","acquired":true,"shares":1213,"price":9.81,"value":11899.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being filed voluntarily to report the acquisition of 1,213 shares by the Reporting Person on June 21, 2019 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":46273,"source":{"system":"sec-edgar","filing":"0001209191-19-038762","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119038762/doc4.xml","form_type":"4"}},{"id":3611876,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock option (right to buy)","published_at":"2019-03-05T16:29:29.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest one year after January 1, 2019 (the \"Vesting Commencement Date\") and thereafter one-forty-eighth (1/48th) of the  total shares shall vest each month following the one year anniversary of the Vesting Commencement Date, so that all of the shares shall be vested four (4) years after the Vesting Commencement Date."}],"balance_after":18000,"derivative":{"exercise_price":14.75,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-19-016506","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119016506/doc4.xml","form_type":"4"}},{"id":3611875,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2019-03-05T16:29:29.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":45060,"source":{"system":"sec-edgar","filing":"0001209191-19-016506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119016506/doc4.xml","form_type":"4"}},{"id":3703809,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2019-01-04T17:12:25.000Z","date":"2019-01-03","kind":"sale","acquired":false,"shares":734,"price":12.36,"value":9072.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares of common stock pursuant to Rule 10b5-1 arrangements to cover tax withholding obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on February 1, 2018."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 922 shares of Common Stock that were acquired by the Reporting Person on December 20, 2018 at $10.48 per share pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":9060,"source":{"system":"sec-edgar","filing":"0001209191-19-002087","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119002087/doc4.xml","form_type":"4"}},{"id":3884933,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2018-06-22T16:30:18.000Z","date":"2018-06-20","kind":"other","acquired":true,"shares":539,"price":21.22,"value":11437.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being filed voluntarily to report the acquisition of 539 shares by the Reporting Person on June 20, 2018 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":8872,"source":{"system":"sec-edgar","filing":"0001209191-18-039211","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118039211/doc4.xml","form_type":"4"}},{"id":4079044,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock option (right to buy)","published_at":"2018-02-02T16:45:08.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":33333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest one year after January 1, 2018; thereafter one-forty-eighth (1/48th) of the shares subject to the option shall vest each month following the one year anniversary of January 1, 2018, so that all of the shares subject to the option shall be vested four (4) years after January 1, 2018."}],"balance_after":33333,"derivative":{"exercise_price":22.31,"expiration_date":"2028-01-31","underlying":"Common Stock","underlying_shares":33333},"source":{"system":"sec-edgar","filing":"0001209191-18-006924","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118006924/doc4.xml","form_type":"4"}},{"id":4079043,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2018-02-02T16:45:08.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8333,"source":{"system":"sec-edgar","filing":"0001209191-18-006924","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118006924/doc4.xml","form_type":"4"}},{"id":4272506,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & General Counsel"}}],"security":"Stock option (right to buy)","published_at":"2017-06-26T21:20:23.000Z","date":"2017-06-26","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on June 26, 2018; thereafter one-forty-eighth (1/48th) of the shares subject to the option shall vest each month following June 26, 2018, so that all of the shares subject to the option shall be vested after June 26, 2021."}],"balance_after":125000,"derivative":{"exercise_price":21.74,"expiration_date":"2027-06-25","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-17-041875","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919117041875/doc4.xml","form_type":"4"}},{"id":4292250,"issuer":{"id":6245,"kind":"organization","name":"Minerva Neurosciences, Inc."},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,General Counsel & Sec."}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-06-05T20:33:12.000Z","date":"2017-06-01","kind":"exercise","acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vested as to 25% for the shares on April 14, 2016 and then in quarterly installments over 3 years thereafter."}],"balance_after":39774,"derivative":{"exercise_price":5.19,"expiration_date":"2025-04-13","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-17-037738","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1598646/000120919117037738/doc4.xml","form_type":"4"}},{"id":4292249,"issuer":{"id":6245,"kind":"organization","name":"Minerva Neurosciences, Inc."},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,General Counsel & Sec."}}],"security":"Common Stock","published_at":"2017-06-05T20:33:12.000Z","date":"2017-06-01","kind":"sale","acquired":false,"shares":17500,"price":11,"value":192500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 22, 2016."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-037738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1598646/000120919117037738/doc4.xml","form_type":"4"}},{"id":4292248,"issuer":{"id":6245,"kind":"organization","name":"Minerva Neurosciences, Inc."},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,General Counsel & Sec."}}],"security":"Common Stock","published_at":"2017-06-05T20:33:12.000Z","date":"2017-06-01","kind":"exercise","acquired":true,"shares":17500,"price":5.19,"value":90825.0,"ownership":{"direct":true},"balance_after":17500,"source":{"system":"sec-edgar","filing":"0001209191-17-037738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598646/000120919117037738/doc4.xml","form_type":"4"}},{"id":4495917,"issuer":{"id":6245,"kind":"organization","name":"Minerva Neurosciences, Inc."},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,General Counsel & Sec."}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-06T21:28:39.000Z","date":"2017-01-04","kind":"exercise","acquired":false,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests as follows: 25% on April 14, 2016; and then in quarterly installments over 3 years thereafter."}],"balance_after":57274,"derivative":{"exercise_price":5.19,"expiration_date":"2025-04-13","underlying":"Common Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001209191-17-002652","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1598646/000120919117002652/doc4.xml","form_type":"4"}},{"id":4495916,"issuer":{"id":6245,"kind":"organization","name":"Minerva Neurosciences, Inc."},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,General Counsel & Sec."}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-06T21:28:39.000Z","date":"2017-01-04","kind":"exercise","acquired":false,"shares":17250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests as follows: 25% on December 4, 2016 and then in quarterly installments over 3 years thereafter."}],"balance_after":51750,"derivative":{"exercise_price":4.71,"expiration_date":"2025-12-03","underlying":"Common Stock","underlying_shares":17250},"source":{"system":"sec-edgar","filing":"0001209191-17-002652","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1598646/000120919117002652/doc4.xml","form_type":"4"}},{"id":4495915,"issuer":{"id":6245,"kind":"organization","name":"Minerva Neurosciences, Inc."},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,General Counsel & Sec."}}],"security":"Common Stock","published_at":"2017-01-06T21:28:39.000Z","date":"2017-01-04","kind":"sale","acquired":false,"shares":17500,"price":12,"value":210000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 22, 2016."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-002652","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1598646/000120919117002652/doc4.xml","form_type":"4"}},{"id":4495914,"issuer":{"id":6245,"kind":"organization","name":"Minerva Neurosciences, Inc."},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,General Counsel & Sec."}}],"security":"Common Stock","published_at":"2017-01-06T21:28:39.000Z","date":"2017-01-04","kind":"exercise","acquired":true,"shares":250,"price":5.19,"value":1297.5,"ownership":{"direct":true},"balance_after":17500,"source":{"system":"sec-edgar","filing":"0001209191-17-002652","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1598646/000120919117002652/doc4.xml","form_type":"4"}},{"id":4495913,"issuer":{"id":6245,"kind":"organization","name":"Minerva Neurosciences, Inc."},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,General Counsel & Sec."}}],"security":"Common Stock","published_at":"2017-01-06T21:28:39.000Z","date":"2017-01-04","kind":"exercise","acquired":true,"shares":17250,"price":4.71,"value":81247.5,"ownership":{"direct":true},"balance_after":17250,"source":{"system":"sec-edgar","filing":"0001209191-17-002652","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598646/000120919117002652/doc4.xml","form_type":"4"}},{"id":4518354,"issuer":{"id":6245,"kind":"organization","name":"Minerva Neurosciences, Inc."},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,General Counsel & Sec."}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-12-16T22:01:16.000Z","date":"2016-12-14","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is the closing price of the Issuer's common stock on December 14, 2016."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option shall vest as follows: 25% on December 14, 2017 and then in quarterly installments over 3 years thereafter."}],"balance_after":35000,"derivative":{"exercise_price":13.45,"expiration_date":"2026-12-13","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-16-155681","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1598646/000120919116155681/doc4.xml","form_type":"4"}},{"id":4518353,"issuer":{"id":6245,"kind":"organization","name":"Minerva Neurosciences, Inc."},"owners":[{"id":62513,"kind":"person","name":"Levine Mark S.","position":1,"cik":"0001617236","reported_name":"Levine Mark S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,General Counsel & Sec."}}],"security":"Restricted Stock Units","published_at":"2016-12-16T22:01:16.000Z","date":"2016-12-14","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents shares issuable upon the vesting of restricted stock units (\"RSUs\") awarded to the Reporting Person on December 14, 2016. The RSUs vest in 4 equal annual installments beginning on December 14, 2017 and will be fully vested on December 14, 2020, in all cases so long as there has been no break in the Reporting Person's continuous service through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents shares issuable upon the vesting of restricted stock units (\"RSUs\") awarded to the Reporting Person on December 14, 2016. The RSUs vest in 4 equal annual installments beginning on December 14, 2017 and will be fully vested on December 14, 2020, in all cases so long as there has been no break in the Reporting Person's continuous service through such date."}],"balance_after":20000,"derivative":{"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-16-155681","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598646/000120919116155681/doc4.xml","form_type":"4"}}]}